<p>Neumora Therapeutics, Inc.（纳斯达克代码：NMRA - 免费报告）- 威廉·布莱尔的股票分析师在 8 月 6 日星期三发布的报告中上调了对 Neumora Therapeutics 2029 财年的每股收益（EPS）预期。威廉·布莱尔的分析师 M. Minter 现在预计该公司将实现每股收益 1.01 美元，高于之前的 0.94 美元的预期。市场普遍预计 Neumora Therapeutics 当前全年的每股收益为（-1.61 美元）。</p>
<p>Neumora Therapeutics（纳斯达克代码：NMRA - 获取免费报告）最近在 8 月 6 日星期三公布了季度财报。该公司报告季度每股收益（EPS）为（-0.33 美元），超出市场普遍预期的（-0.38 美元）0.05 美元。</p>
<p>获取 <strong>Neumora Therapeutics</strong> 的提醒：</p>
<p>其他一些研究公司最近也对 NMRA 发布了报告。Needham &amp; Company LLC 在 5 月 13 日星期二的报告中重申了对 Neumora Therapeutics 的 “买入” 评级，并设定了 5.00 美元的目标价。瑞穗证券在 7 月 16 日星期三的研究报告中将 Neumora Therapeutics 的目标价从 4.00 美元上调至 5.00 美元，并给予该股票 “跑赢大盘” 的评级。一位分析师对该股票给予了卖出评级，五位分析师给予了持有评级，三位分析师给予了买入评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “持有”，平均目标价为 7.14 美元。</p>
<p><strong>阅读我们关于 Neumora Therapeutics 的最新股票报告</strong></p>
<h2>Neumora Therapeutics 股票下跌 6.4%</h2>
<p>在周五的午盘交易中，纳斯达克：NMRA 的股票下跌 0.11 美元，达到 1.55 美元。该股票的交易量为 189,456 股，而其平均交易量为 2,133,940 股。该公司的市值为 2.499 亿美金，市盈率为-0.99，贝塔值为 2.91。Neumora Therapeutics 的股价在过去一年内最低为 0.61 美元，最高为 17.19 美元。该股票的 50 日简单移动平均线为 1.23 美元，200 日简单移动平均线为 1.19 美元。</p>
<h2>Neumora Therapeutics 的机构交易</h2>
<p>几家机构投资者最近增加或减少了在 NMRA 的持股。Lunate Capital Ltd 在第一季度收购了 Neumora Therapeutics 的新股份，价值 212.4 万美元。Schonfeld Strategic Advisors LLC 在第四季度将其在 Neumora Therapeutics 的持股增加了 273.9%。Schonfeld Strategic Advisors LLC 现在拥有 521,013 股该公司的股票，价值 552.3 万美元，此前在上个季度购买了 381,676 股。Capital International Investors 在第四季度将其在 Neumora Therapeutics 的持股增加了 692.1%。Capital International Investors 现在拥有 3,700,359 股该公司的股票，价值 3922.4 万美元，此前在上个季度购买了 3,233,179 股。Ameriprise Financial Inc.在第四季度购买了 Neumora Therapeutics 的新股份，价值约 125.8 万美元。最后，加利福尼亚州教师退休系统在第四季度将其在 Neumora Therapeutics 的持股增加了 793.5%。加利福尼亚州教师退休系统现在拥有 54,457 股该公司的股票，价值 577,000 美元，此前在上个季度购买了 48,362 股。目前 47.65% 的股票由机构投资者持有。</p>
<h2>关于 Neumora Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Neumora Therapeutics, Inc.是一家临床阶段的生物制药公司，专注于开发针对脑疾病、神经精神疾病和神经退行性疾病的治疗方法。该公司开发了 navacaprant（NMRA-140），这是一种新型的每日一次口服的κ-阿片受体拮抗剂，目前正在进行针对重度抑郁症的三期临床试验。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Neumora Therapeutics</li>
<li>电话会议和个人投资者</li>
<li>特斯拉在刀刃上保持平衡：谨慎行事的时机</li>
<li>如何在购买前评估一只股票</li>
<li>为什么 Axon 的 16% 激增预示着公共安全技术的新纪元</li>
<li>ETF 筛选器：用途和逐步指南</li>
<li>DraftKings 发布创纪录季度，瞄准盈利能力</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Tk1SQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Tk1SQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Neumora Therapeutics 吗？</h2>
<p>在考虑 Neumora Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Neumora Therapeutics 并不在名单上。</p>
<p>虽然 Neumora Therapeutics 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

NMRA

<p>威廉·布莱尔已将 Neumora Therapeutics（NASDAQ:NMRA）2029 财年的每股收益预期从 0.94 美元上调至 1.01 美元。该公司最近报告的季度每股收益为（0.33 美元），超过了市场共识预期的（0.38 美元）。Neumora 的股票目前下跌 6.4%，交易价格为 1.55 美元，市值为 2.499 亿美金。分析师对该股票的评级不一，市场共识评级为 “持有”，平均目标价格为 7.14 美元</p>

<p>Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Stock analysts at William Blair raised their FY2029 earnings per share (EPS) estimates for Neumora Therapeutics in a report released on Wednesday, August 6th. William Blair analyst M. Minter now expects that the company will earn $1.01 per share for the year, up from their previous estimate of $0.94. The consensus estimate for Neumora Therapeutics' current full-year earnings is ($1.61) per share.</p>
<div class="lb-trans"><p>Neumora Therapeutics, Inc.（纳斯达克代码：NMRA - 免费报告）- 威廉·布莱尔的股票分析师在 8 月 6 日星期三发布的报告中上调了对 Neumora Therapeutics 2029 财年的每股收益（EPS）预期。威廉·布莱尔的分析师 M. Minter 现在预计该公司将实现每股收益 1.01 美元，高于之前的 0.94 美元的预期。市场普遍预计 Neumora Therapeutics 当前全年的每股收益为（-1.61 美元）。</p>
</div><p>Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.05.</p>
<div class="lb-trans"><p>Neumora Therapeutics（纳斯达克代码：NMRA - 获取免费报告）最近在 8 月 6 日星期三公布了季度财报。该公司报告季度每股收益（EPS）为（-0.33 美元），超出市场普遍预期的（-0.38 美元）0.05 美元。</p>
</div><p>Get <strong>Neumora Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Neumora Therapeutics</strong> 的提醒：</p>
</div><p>A number of other research firms also recently issued reports on NMRA. Needham &amp; Company LLC reiterated a &#34;buy&#34; rating and set a $5.00 price objective on shares of Neumora Therapeutics in a report on Tuesday, May 13th. Mizuho lifted their target price on Neumora Therapeutics from $4.00 to $5.00 and gave the stock an &#34;outperform&#34; rating in a research note on Wednesday, July 16th. One analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of &#34;Hold&#34; and an average target price of $7.14.</p>
<div class="lb-trans"><p>其他一些研究公司最近也对 NMRA 发布了报告。Needham &amp; Company LLC 在 5 月 13 日星期二的报告中重申了对 Neumora Therapeutics 的 “买入” 评级，并设定了 5.00 美元的目标价。瑞穗证券在 7 月 16 日星期三的研究报告中将 Neumora Therapeutics 的目标价从 4.00 美元上调至 5.00 美元，并给予该股票 “跑赢大盘” 的评级。一位分析师对该股票给予了卖出评级，五位分析师给予了持有评级，三位分析师给予了买入评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “持有”，平均目标价为 7.14 美元。</p>
</div><p><strong>Read Our Latest Stock Report on Neumora Therapeutics</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Neumora Therapeutics 的最新股票报告</strong></p>
</div><h2>Neumora Therapeutics Stock Down 6.4%</h2>
<div class="lb-trans"><h2>Neumora Therapeutics 股票下跌 6.4%</h2>
</div><p>Shares of NASDAQ:NMRA traded down $0.11 during mid-day trading on Friday, reaching $1.55. 189,456 shares of the stock were exchanged, compared to its average volume of 2,133,940. The company has a market cap of $249.90 million, a P/E ratio of -0.99 and a beta of 2.91. Neumora Therapeutics has a one year low of $0.61 and a one year high of $17.19. The stock's 50 day simple moving average is $1.23 and its 200-day simple moving average is $1.19.</p>
<div class="lb-trans"><p>在周五的午盘交易中，纳斯达克：NMRA 的股票下跌 0.11 美元，达到 1.55 美元。该股票的交易量为 189,456 股，而其平均交易量为 2,133,940 股。该公司的市值为 2.499 亿美金，市盈率为-0.99，贝塔值为 2.91。Neumora Therapeutics 的股价在过去一年内最低为 0.61 美元，最高为 17.19 美元。该股票的 50 日简单移动平均线为 1.23 美元，200 日简单移动平均线为 1.19 美元。</p>
</div><h2>Institutional Trading of Neumora Therapeutics</h2>
<div class="lb-trans"><h2>Neumora Therapeutics 的机构交易</h2>
</div><p>Several institutional investors have recently added to or reduced their stakes in NMRA. Lunate Capital Ltd acquired a new position in Neumora Therapeutics in the 1st quarter valued at $2,124,000. Schonfeld Strategic Advisors LLC increased its holdings in Neumora Therapeutics by 273.9% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 521,013 shares of the company's stock worth $5,523,000 after purchasing an additional 381,676 shares in the last quarter. Capital International Investors increased its holdings in Neumora Therapeutics by 692.1% in the 4th quarter. Capital International Investors now owns 3,700,359 shares of the company's stock worth $39,224,000 after purchasing an additional 3,233,179 shares in the last quarter. Ameriprise Financial Inc. bought a new stake in shares of Neumora Therapeutics in the 4th quarter valued at about $1,258,000. Finally, California State Teachers Retirement System grew its position in shares of Neumora Therapeutics by 793.5% in the 4th quarter. California State Teachers Retirement System now owns 54,457 shares of the company's stock valued at $577,000 after buying an additional 48,362 shares during the last quarter. 47.65% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者最近增加或减少了在 NMRA 的持股。Lunate Capital Ltd 在第一季度收购了 Neumora Therapeutics 的新股份，价值 212.4 万美元。Schonfeld Strategic Advisors LLC 在第四季度将其在 Neumora Therapeutics 的持股增加了 273.9%。Schonfeld Strategic Advisors LLC 现在拥有 521,013 股该公司的股票，价值 552.3 万美元，此前在上个季度购买了 381,676 股。Capital International Investors 在第四季度将其在 Neumora Therapeutics 的持股增加了 692.1%。Capital International Investors 现在拥有 3,700,359 股该公司的股票，价值 3922.4 万美元，此前在上个季度购买了 3,233,179 股。Ameriprise Financial Inc.在第四季度购买了 Neumora Therapeutics 的新股份，价值约 125.8 万美元。最后，加利福尼亚州教师退休系统在第四季度将其在 Neumora Therapeutics 的持股增加了 793.5%。加利福尼亚州教师退休系统现在拥有 54,457 股该公司的股票，价值 577,000 美元，此前在上个季度购买了 48,362 股。目前 47.65% 的股票由机构投资者持有。</p>
</div><h2>About Neumora Therapeutics</h2>
<div class="lb-trans"><h2>关于 Neumora Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.</p>
<div class="lb-trans"><p>Neumora Therapeutics, Inc.是一家临床阶段的生物制药公司，专注于开发针对脑疾病、神经精神疾病和神经退行性疾病的治疗方法。该公司开发了 navacaprant（NMRA-140），这是一种新型的每日一次口服的κ-阿片受体拮抗剂，目前正在进行针对重度抑郁症的三期临床试验。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Neumora Therapeutics</li>
<li>Conference Calls and Individual Investors</li>
<li>Tesla Is Balanced on a Knife Edge: Time to Tread Carefully</li>
<li>How to Evaluate a Stock Before Buying</li>
<li>Why Axon's 16% Surge Signals a New Era in Public Safety Tech</li>
<li>ETF Screener: Uses and Step-by-Step Guide</li>
<li>DraftKings Posts Record Quarter, Eyes Profitability</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Neumora Therapeutics</li>
<li>电话会议和个人投资者</li>
<li>特斯拉在刀刃上保持平衡：谨慎行事的时机</li>
<li>如何在购买前评估一只股票</li>
<li>为什么 Axon 的 16% 激增预示着公共安全技术的新纪元</li>
<li>ETF 筛选器：用途和逐步指南</li>
<li>DraftKings 发布创纪录季度，瞄准盈利能力</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Tk1SQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=NMRA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Neumora Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Neumora Therapeutics 吗？</h2>
</div><p>Before you consider Neumora Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Neumora Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neumora Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Neumora Therapeutics 并不在名单上。</p>
</div><p>While Neumora Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Neumora Therapeutics 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

William Blair 对 Neumora Therapeutics 2029 财年的收益预测是多少？